Literature DB >> 28402983

Comparison of pro re nata versus Bimonthly Injection of Intravitreal Aflibercept for Typical Neovascular Age-Related Macular Degeneration.

Ryusaburo Mori1, Koji Tanaka, Miho Haruyama, Akiyuki Kawamura, Koichi Furuya, Mitsuko Yuzawa.   

Abstract

PURPOSE: The aim of this study was to clarify the 1-year outcomes of pro re nata (PRN) and bimonthly intravitreal injections of aflibercept (IVA) for typical neovascular age-related macular degeneration (tAMD) after the initial 3 monthly IVA.
METHODS: We conducted a prospective, interventional study. Fifty-eight treatment-naïve patients with tAMD were randomly assigned to the PRN (30 patients) or the bimonthly (28 patients) treatment group. Both groups initially received 3 monthly IVA. Visual acuity, central macular retinal thickness (CRT), and central choroidal thickness (CCT) were evaluated at 12 months. Subanalysis was performed to identify factors associated with the best-corrected visual acuity (BCVA).
RESULTS: BCVA was significantly improved only in the bimonthly group at 12 months. CRT and CCT were significantly decreased in both groups. Subanalysis showed that the only factor associated with BCVA improvement at 12 months was the existence of pigment epithelial detachment at baseline.
CONCLUSIONS: BCVA showed significant improvement only in the bimonthly group but not in the PRN group at 12 months.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Aflibercept; Bimonthly injection; Typical neovascular age-related macular degeneration; pro re nata injection

Mesh:

Substances:

Year:  2017        PMID: 28402983     DOI: 10.1159/000468950

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  5 in total

1.  Comparative Effectiveness of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Managing Neovascular Age-Related Macular Degeneration: A Meta-Analysis.

Authors:  Frédéric Matonti; Jean-François Korobelnik; Corinne Dot; Vincent Gualino; Vincent Soler; Sarah Mrejen; Marie-Noëlle Delyfer; Stéphanie Baillif; Maté Streho; Pierre Gascon; Catherine Creuzot-Garcher; Laurent Kodjikian
Journal:  J Clin Med       Date:  2022-03-25       Impact factor: 4.241

Review 2.  Effect of Anti-VEGF Therapy on the Disease Progression of Neovascular Age-Related Macular Degeneration: A Systematic Review and Model-Based Meta-Analysis.

Authors:  Kenneth T Luu; Jennifer Seal; Michelle Green; Carolyn Winskill; Mayssa Attar
Journal:  J Clin Pharmacol       Date:  2022-01-05       Impact factor: 2.860

Review 3.  Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis.

Authors:  Andi Arus Victor; Yan Martha Putri
Journal:  Int J Retina Vitreous       Date:  2022-09-22

4.  Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.

Authors:  Emily Li; Simone Donati; Kristina B Lindsley; Magdalena G Krzystolik; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2020-05-05

Review 5.  Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression.

Authors:  Daniele Veritti; Valentina Sarao; Valentina Soppelsa; Carla Danese; Jay Chhablani; Paolo Lanzetta
Journal:  J Clin Med       Date:  2022-01-10       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.